…other Zeman criteria, 15 out of 83 patients (18%) were diagnosed with definite TEA (instead of TGA), and 4 more with possible epilepsy. Does this mean that every amnesia patient…
Content Section:
Articles
…talk “Why we have to rethink” referring to strategies for NCD. Supported by the Charlie Foundation, he introduced the first topic in neurology, epilepsy and KD. Michel Lundell, from Sweden,…
Content Section:
Conference Reports
…£50-80 https://fitwise.eventsair.com/basp-trainees-teaching/ 14th World Congress on Controversies in Neurology London 26-29/3/20 £240-650 http://cony.comtecmed.com/cony-2020-als-program/ 4th ILEA British Branch Epilepsy Neuroimaging Course Chalfont St Peter 26-28/3/20 £450-550 https://www.ilae.org/congresses/4th-ilae-british-branch-epilepsy-neuroimaging-course 20th Annual Course: Neuroradiology…
Content Section:
Event News
…2015 for her services to children with epilepsy, Professor Cross is currently Prince of Wales’s Chair of Childhood Epilepsy at UCL-Great Ormond Street Institute of Child Health, Great Ormond Street…
Content Section:
News Posts
…talks focused on better prevention of stroke and dementia, but also preventing progressive disabilities for patients suffering from long-term conditions such as epilepsy and migraine. The EAN issued a statement…
Content Section:
Conference Reports
…Ketogenic Dietary Therapy (KDT) in epilepsy and other neurological conditions. Due to restrictions in place due to COVID19 KetoConference is being held virtually this year with a shorter than usual…
Content Section:
Event News
…disease, stem cells, and the role of vitamins in neuronal development and neural repair. Read more about Rosemary Marco Mula MD, PhD, FRCP, FEAN Editor of our Epilepsy Section. He…
Content Section:
Pages
…and cognitive symptoms) allows precise diagnosis of the cause of symptoms (e.g. post-traumatic migraine, vestibular disorders, epilepsy), whether they have a physiological or structural origin, and enables individualised investigation and…
Content Section:
Articles
…with LGS, a rare and devastating lifelong childhood-onset epilepsy5 UCB, a global biopharmaceutical company, announced on May 2, 2022 the publication in JAMA Neurology of its multi-centre, double-blind, placebo-controlled, parallel-group,…
Content Section:
News Posts